Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activating transcription factor 5 (ATF5) is a member of the basic leucine zipper (bZip) family of transcription factors within the cAMP response element-binding protein lineage. ATF5 regulates gene expression in response to cellular stress and is involved in the control of cell survival, apoptosis, cell cycle, and differentiation, particularly within the central nervous system and in developing neural tissues. It is upregulated in a variety of cancers, where it promotes tumor growth and survival, and is implicated in oncogenesis and resistance to apoptosis. Targeting ATF5 with dominant-negative peptides has shown preclinical efficacy in inducing tumor regression, highlighting its potential as a therapeutic target in oncology. ATF5 also has roles in mitochondrial homeostasis, the unfolded protein response, and maintenance of centrosome integrity during cell division, linking its activity to genome stability and cancer biology.
Inhibition of ATF5's pro-survival transcriptional activity, leading to tumor regression and apoptosis in cancer cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activating transcription factor 5 (ATF5).